ZDF
Sign inSign up

Vulnerabilities

Vulnerability · CVE-2026-108452

Improper limitation of a pathname to a restricted directory ('path traversal') in Microsoft Office SharePoint allows an authorized attacker to execute code over a network.

Published Oct 15, 2026 · catalog updated Oct 16, 2026 · Microsoft SharePoint

Check if you run it

No confirmed exploitation is on record for CVE-2026-108452. EPSS is 0.63%. Act only if a listed version of Microsoft SharePoint is installed.

Gaps on this record

  • No version range is stored. A customer cannot check an installed version against this record.
  • No vendor fix or required action is stored. Compare the linked advisory before you change production.
Severity
High8.8
Known exploitation
Not in CISA/VulnCheck KEV
EPSS
0.63%
Remediation
Advisory link
Affected products
microsoft Microsoft SharePoint Server Subscription Edition · vendor Microsoft Microsoft SharePoint Server Subscription Edition

Improper limitation of a pathname to a restricted directory ('path traversal') in Microsoft Office SharePoint allows an authorized attacker to execute code over a network.

Are you affected?

Enter the version you run. The result uses only the ranges stored on this record.

The check returns affected, not affected, or incomplete. It does not guess a version that is missing from the record.

  • microsoft Microsoft SharePoint Server Subscription Editionversion unspecified
  • vendor Microsoft Microsoft SharePoint Server Subscription Editionversion unspecified

How to fix CVE-2026-108452

What to do

Three questions, each answered from this record only. Confirm the vendor advisory before you patch.

Should you patch?

No confirmed exploitation is on record for CVE-2026-108452. EPSS is 0.63%. Act only if a listed version of Microsoft SharePoint is installed.

Which versions are affected?

Affected version ranges are not on this record. Compare the installed version with the linked vendor advisory before you change production.

What should an analyst verify?

CWE-22: Path Traversal. EPSS 0.63%. There is no CISA KEV listing. No Exploit-DB or Metasploit reference is linked. Use the source links for the original advisory.

Code

The project this record applies to. Exploit listings stay in References.

No public source repository is identified for this product.

Timeline

Detection, updates, and resolution for this record.

  1. Oct 15, 2026 · NIST NVD

    Detected

    Improper limitation of a pathname to a restricted directory ('path traversal') in Microsoft Office SharePoint allows an authorized attacker to execute code over a network.

  2. Oct 15, 2026 · CVE.org

    Updated

    Improper limitation of a pathname to a restricted directory ('path traversal') in Microsoft Office SharePoint allows an authorized attacker to execute code over a network.

  3. Oct 16, 2026 · NIST NVD

    Updated

    Improper limitation of a pathname to a restricted directory ('path traversal') in Microsoft Office SharePoint allows an authorized attacker to execute code over a network.

Sources

  • CVE.orgVulnerability recordCVE-2026-108452

    Improper limitation of a pathname to a restricted directory ('path traversal') in Microsoft Office SharePoint allows an authorized attacker to execute code over a network.

    cve.org
  • FIRST EPSSExploitation probabilityCVE-2026-108452

    30-day exploitation probability 0.6%

    first.org
  • Microsoft Security Update GuideVendor advisoryCVE-2026-108452

    Microsoft SharePoint Server Subscription Edition

    msrc.microsoft.com
  • NIST NVDVulnerability recordCVE-2026-108452

    Improper limitation of a pathname to a restricted directory ('path traversal') in Microsoft Office SharePoint allows an authorized attacker to execute code over a network.

    nvd.nist.gov
  • Tenable CVE DatabaseVulnerability recordCVE-2026-108452

    Improper limitation of a pathname to a restricted directory ('path traversal') in Microsoft Office SharePoint allows an authorized attacker to execute code over a network.

    tenable.com

References

Freshness

Last verified in this catalog Oct 18, 2026. Significant claims (KEV, EPSS, CVSS, affected ranges) come from the source rows above — open the original publisher for the authoritative advisory.